# barchart

# IMMUCELL CORP /DE/

# FORM 8-K

(Current Report Filing)

# Filed 11/13/23 for the Period Ending 11/13/23

Address 56 EVERGREEN DR, PORTLAND, ME, 04103

Telephone (727) 384-2323

CIK 0000811641

Symbol ICCC

SIC Code 2835 - In Vitro & In Vivo Diagnostic Substances

Fiscal Year 12/31

# Powered by **barchart**

https://www.barchart.com/solutions
© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 13, 2023

	illilliuceli corporation	
(Exa	ct name of registrant as specified in its c	harter)
DE	001-12934	01-0382980
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
56 Evergreen Drive Portland, Maine		04103
(Address of principal executive offices)		(Zip Code)
Registrant's	telephone number, including area code	207-878-2770
(Former r	name or former address, if changed since	last report)
Check the appropriate box below if the Forunder any of the following provisions:	rm 8-K filing is intended to simultaneousl	y satisfy the filing obligation of the Registrant
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
☐ Soliciting material pursuant to Rule 14	a-12 under the Exchange Act (17 CFR 24	0.14a-12)
☐ Pre-commencement communications p	oursuant to Rule 14d-2(b) under the Exch	ange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications p	oursuant to Rule 13e-4(c) under the Exch	ange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 1	.2(b) of the Act:	
Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, \$0.10 par value per share	ICCC	Nasdaq
1933 (§230.405 of this chapter) or Rule 12b-2 Emerging growth company $\Box$	of the Securities Exchange Act of 1934 (	ed not to use the extended transition period for

# Item 2.02. Results of Operations and Financial Condition

On November 13, 2023 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended September 30, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

# Item 9.01. Financial Statements and Exhibits.

## (d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

### 99.1 Press Release of ImmuCell Corporation dated November 13, 2023.

104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

1

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **IMMUCELL CORPORATION**

Date: November 13, 2023 By: <u>/s/ Michael F. Brigham</u>

Michael F. Brigham

President, Chief Executive Officer and

Principal Financial Officer

2

### **Exhibit Index**

# **Exhibit No. Description**

99.1 Press Release of ImmuCell Corporation dated November 13, 2023

104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).